Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.
PSMA - prostate specific membrane antigen
castration-resistance prostate cancer
crpc
neuroendocrine prostate cancer (NEPC)
small cell prostate cancer
theranostic PSMA radioligands
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
05
2022
accepted:
13
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
The development of a neuroendocrine phenotype as a mechanism of resistance to hormonal treatment is observed in up to 20% of advanced prostate cancer patients. High grade neuroendocrine prostate cancer (NEPC) is associated to poor prognosis and the therapeutic armamentarium is restricted to platinum-based chemotherapy. Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) imaging has recently emerged as a potential new standard for the staging of prostate cancer and PSMA-based radioligand therapy (RLT) as a therapeutic option in advanced metastatic castration resistant prostate cancer (mCRPC). PSMA-based theranostic is not currently applied in the staging and treatment of NEPC since PSMA expression on neuroendocrine differentiated cells was shown to be lost. In this case series, we present 3 consecutive mCRPC patients with histologically proven high grade neuroendocrine differentiation who underwent PSMA-PET/CT and surprisingly showed high tracer uptake. This observation stimulates further research on the use of PSMA-based theranostic in the management of NEPC.
Identifiants
pubmed: 35936689
doi: 10.3389/fonc.2022.937713
pmc: PMC9354022
doi:
Types de publication
Case Reports
Langues
eng
Pagination
937713Informations de copyright
Copyright © 2022 Bergamini, Dalla Volta, Caramella, Bercich, Fisogni, Bertoli, Valcamonico, Grisanti, Poliani, Bertagna and Berruti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Am J Surg Pathol. 2014 Jun;38(6):756-67
pubmed: 24705311
Clin Cancer Res. 2009 Aug 1;15(15):4792-8
pubmed: 19638458
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
J Urol. 2022 Jul;208(1):90-99
pubmed: 35227084
Prostate. 2009 Jul 1;69(10):1101-8
pubmed: 19343734
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136
pubmed: 28765998
Am J Clin Exp Urol. 2014 Dec 09;2(4):273-85
pubmed: 25606573
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30
pubmed: 27136743
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894499
Cancer Cell. 2016 Apr 11;29(4):536-547
pubmed: 27050099
Clin Nucl Med. 2022 Mar 1;47(3):e259-e261
pubmed: 35025791
Clin Cancer Res. 2021 Feb 1;27(3):759-774
pubmed: 33199493
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
Clin Nucl Med. 2019 Jan;44(1):53-54
pubmed: 30325820
J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129
pubmed: 17631319
J Nucl Med. 2020 Nov;61(11):1602-1606
pubmed: 32169910
Ann Oncol. 2001;12 Suppl 2:S159-64
pubmed: 11762345
World J Surg Oncol. 2008 Jun 19;6:64
pubmed: 18565231
Cancer Res. 2021 Sep 15;81(18):4736-4750
pubmed: 34312180
Clin Cancer Res. 2019 Dec 1;25(23):6916-6924
pubmed: 31363002
Prostate. 2014 Aug;74(11):1153-9
pubmed: 24913988
Endocr Relat Cancer. 2005 Mar;12(1):109-17
pubmed: 15788643
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
Clin Nucl Med. 2015 Feb;40(2):e163-6
pubmed: 25275415
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482
pubmed: 29686080
Cancer Discov. 2011 Nov;1(6):487-95
pubmed: 22389870
Am J Surg Pathol. 2006 Jun;30(6):705-12
pubmed: 16723847
Clin Genitourin Cancer. 2017 Feb;15(1):e65-e68
pubmed: 27751686
Clin Nucl Med. 2016 Dec;41(12):959-960
pubmed: 27764046
Handb Exp Pharmacol. 2018;249:181-194
pubmed: 28353036
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Clin Nucl Med. 2017 May;42(5):410-413
pubmed: 28240661
J Nucl Med. 2020 Jun;61(6):904-910
pubmed: 31806771